Home
Sun Pharmaceuticals Industries Ltd EPS

Sun Pharmaceuticals Industries Ltd
NSE: SUNPHARMA
EPS
Key Highlights
- The Earning per Share of Sun Pharmaceuticals Industries Ltd is ₹ 49.16 as of 21 Feb 25 .
- The earning per share of Sun Pharmaceuticals Industries Ltd changed from ₹ 8.4 to ₹ 12.1 over 7 quarters. This represents a CAGR of 23.19% .
Historical Earning per Share of Sun Pharmaceuticals Industries Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Sun Pharmaceuticals Industries Ltd
Company Fundamentals for Sun Pharmaceuticals Industries Ltd
Market Cap
394,222 Cr
EPS
49.2
P/E Ratio (TTM)
33.4
P/B Ratio (TTM)
5.7
Day’s High
1681.25
Day’s Low
1632.0
DTE
0.0
ROE
16.0
52 Week High
1960.2
52 Week Low
1376.75
ROCE
18.1
Market Price of Sun Pharmaceuticals Industries Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 1643.05 |
20 Feb 2025 | 1669.7 |
19 Feb 2025 | 1678 |
18 Feb 2025 | 1701.55 |
17 Feb 2025 | 1713.4 |
14 Feb 2025 | 1704.65 |
13 Feb 2025 | 1746.5 |
12 Feb 2025 | 1693.65 |
11 Feb 2025 | 1699.75 |
10 Feb 2025 | 1732.55 |
SWOT Analysis Of Sun Pharmaceuticals Industries Ltd
BlinkX Score for Sun Pharmaceuticals Industries Ltd
Asset Value vs Market Value of Sun Pharmaceuticals Industries Ltd
Market Value
₹ 3,94,223
Asset Value
Value addition
8.6 X
₹ 40,926
* All values are in ₹ crores
Competitive Comparison of EPS
Company | Market Cap | EPS |
---|
Sun Pharmaceuticals Industries Ltd | 394222 | 49.16 |
Divis Laboratories Ltd | 152610 | 77.86 |
Cipla Ltd | 119067 | 61.78 |
Torrent Pharmaceuticals Ltd | 102739 | 55.02 |
Dr Reddys Laboratories Ltd | 96124 | 64.37 |
Mankind Pharma Ltd | 95999 | 49.48 |
Company | |
---|---|
Sun Pharmaceuticals Industries Ltd | 394222 |
Divis Laboratories Ltd | 152610 |
Cipla Ltd | 119067 |
Torrent Pharmaceuticals Ltd | 102739 |
Dr Reddys Laboratories Ltd | 96124 |
Mankind Pharma Ltd | 95999 |
Historical Market Cap of Sun Pharmaceuticals Industries Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Sun Pharmaceuticals Industries Ltd
Historical Revenue of Sun Pharmaceuticals Industries Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Sun Pharmaceuticals Industries Ltd
Historical EBITDA of Sun Pharmaceuticals Industries Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Sun Pharmaceuticals Industries Ltd
Historical Net Profit of Sun Pharmaceuticals Industries Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Sun Pharmaceuticals Industries Ltd
Dividend Payout Over Time
Sun Pharmaceuticals Industries Ltd News Hub
Sun Pharmaceuticals Industries Ltd spurts 0.31%, up for fifth straight session
Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting a
Read more
20 Aug 24
Sun Pharmaceutical to invest USD 15 mn in Pharmazz Inc.
Sun Pharmaceutical Industries has entered into an agreement with Pharmazz Inc. Delaware US, pursuant
Read more
14 Aug 24
Sun Pharma Q1 PAT climbs 40% YoY to Rs 2,835 cr
Profit before tax was at Rs 3,423.5 crore in Q1 FY25, registering a growth of 37.98% on YoY basis. D
Read more
01 Aug 24
Sun Pharmaceuticals Industries consolidated net profit rises 40.20% in the June 2024 quarter
Net profit of Sun Pharmaceuticals Industries rose 40.20% to Rs 2835.62 crore in the quarter ended Ju
Read more
01 Aug 24
Document
Concalls
July 2024
PPTMay 2024
TranscriptMar 2024
PPTFeb 2024
TranscriptJan 2024
PPTNov 2023
TranscriptSep 2023
PPTMay 2023
TranscriptApr 2023
PPTNov 2022
TranscriptSep 2022
PPTAug 2022
TranscriptJune 2022
TranscriptMar 2022
PPTFeb 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptJune 2021
TranscriptJan 2021
TranscriptJuly 2024
PPTMay 2024
TranscriptMar 2024
PPTFeb 2024
TranscriptJan 2024
PPTNov 2023
TranscriptSep 2023
PPTMay 2023
TranscriptApr 2023
PPTNov 2022
TranscriptSep 2022
PPTAug 2022
TranscriptJune 2022
TranscriptMar 2022
PPTFeb 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptJune 2021
TranscriptJan 2021
Transcript